Endo International (ENDP): Vasopressin Headlines Likely Worse than Reality - Citi
Tweet
Share
E-mail
Get Alerts ENDP Hot Sheet
Price: $0.29 --0%
Rating Summary:
14 Buy, 15 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Rating Summary:
14 Buy, 15 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Join SI Premium – FREE
Citi analyst Liav Abraham weighed in on Endo International plc (NASDAQ: ENDP) following news Athenex lanched a compounded Vasopressin. Abraham said the headline is likely worse than reality.
The firm reiterated a Buy rating and price target of $19.00
For an analyst ratings summary and ratings history on Endo International plc click here. For more ratings news on Endo International plc click here.
Shares of Endo International plc closed at $15.65 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA: classifies Insulet OmniPod pods recall as Class I due to serious injury risk
- RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
- Goldman Sachs Upgrades AP Moller Maersk (MAERSKB:DC) (AMKBY) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, FDA, Trader TalkRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
